


Cite this: *RSC Adv.*, 2025, 15, 2217

Carbon dots with red emission as nanoprobe for sensing of heparin in biofluids and pharmaceutical samples†

Mohammad Safarpour,^a Rassoul Dinarvand,^b ^{*a} Mehrorang Ghaedi ^{*b} and Arash Asfaram ^c

Heparin (HEP) is one of the oldest anticoagulant drugs, widely used in clinical settings, particularly in surgery and dialysis machines. Despite its long history, it remains extensively employed in medical practice. This study introduces a selective and cost-effective method for the rapid detection of HEP using red-emission carbon dots (R-CDs). These R-CDs were synthesized through a one-pot hydrothermal method, utilizing neutral red and thiourea for photostability, biocompatibility, and low cytotoxicity. Key parameters affecting the sensing process, including nanoprobe volume, pH, buffer type, and incubation time, were optimized to achieve potential assay conditions. The fluorescence intensity of the nanoprobe at 625 nm gradually decreased as the concentration of HEP increased from 60 to 240 nM. These changes in fluorescence intensity showed a linear relationship with HEP concentration within this range, achieving a limit of detection (LOD) of 5 nM. The proposed nanoprobe facilitates both quantitative and qualitative non-invasive analysis of HEP in various human biofluids, suggesting their potential for broader bioanalytical applications.

Received 14th September 2024
Accepted 21st November 2024

DOI: 10.1039/d4ra06655c

rsc.li/rsc-advances

1. Introduction

Heparin (HEP) is a linear polysaccharide with high sulfation, characterized by a primary disaccharide repeating unit composed of linked iduronic acid and glucosamine residues.¹ With its abundance of sulfo and carboxyl groups, HEP possesses the highest negative charge density among known biomolecules.^{2,3} This biomolecule uniquely binds to anti-thrombin, accelerating the interaction between antithrombin and thrombin, leading to thrombin-inactivation blood coagulation.⁴ Consequently, HEP is extensively applied in clinical settings as an anticoagulant. However, the improper use of HEP can lead to adverse effects, such as heparin-induced thrombocytopenia (HIT).⁵ Moreover, the precise monitoring of HEP dosage is critical during treatment, as overdosing can result in severe complications, including hemorrhage and osteoporosis.⁶ For cardiovascular surgery, a dosage range of 2–8 U mL^{−1} is considered appropriate, while for postoperative and long-term treatment, a range of 0.2–1.2 U mL^{−1} is recommended.

Currently, HEP dosage in clinical settings is typically monitored using activated clotting time (ACT), activated partial thromboplastin time (aPTT), or anti-factor Xa assays.^{7,8} Although these methods are well established, they have inherent limitations, such as indirect measurement and lack of precision, underscoring the need for novel analytical methods to measure HEP concentrations in blood samples.^{9,10}

HEP injections prevent the formation of harmful blood clots in blood vessels, the heart, and the lungs, playing a vital role during surgery, such as open-heart and bypass procedures. They are also crucial for kidney dialysis and blood transfusions. Although commonly referred to as a “blood thinner”, HEP does not dissolve clots, but prevents their growth. HEP is also used in diagnosing and treating severe blood disorders.¹¹ Recent studies suggest that HEP also exhibits anti-tumor properties and hypolipidemic effects. Given the varying dosages required for surgical cardiovascular treatment and long-term therapy, the accurate and sensitive measurement of HEP levels is essential.¹²

Several sensors for HEP detection have been reported (Table 1), including HPLC/resonance light scattering detection,¹³ fluorometry^{14–18} and colorimetry.^{19–21} While effective, these methods have limitations such as high cost, complexity, time consumption, environmental hazards, and the need for rare reagents, emphasizing the necessity for simpler analytical methods for HEP determination.²² HEP detection could benefit from newly developed sensing probes capable of measuring various non-fluorescent compounds.^{23–27}

^aNanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. E-mail: dinarvand@tums.ac.ir

^bChemistry Department, Yasouj University, Yasouj 75918-74831, Iran. E-mail: m_ghaedi@mail.yu.ac.ir

^cMedicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d4ra06655c>



Table 1 A comparison of the applicability of the proposed sensor with other reported sensors for HEP detection

Method	LOD	LDR	Time (min)	Sample	Ref.
HPLC	0.2 mg L ⁻¹	0.5–10 mg L ⁻¹	—	Serum	13
Spectrofluorimetry	8.2 nM	10–100 nM	—	Injection form	18
Spectrofluorimetry	1.41 µg mL ⁻¹	6–20 µg mL ⁻¹	3.5	Injection form	17
Spectrofluorimetry	10 µg mL ⁻¹	14.4–72 µg mL ⁻¹	5	Serum	16
Spectrofluorimetry	0.01 mg mL ⁻¹	0.01–4 mg mL ⁻¹	—	Urine	15
Spectrofluorimetry	0.4 µM	0–16 µM	—	Injection form	14
Colorimetry	90 nM	0–60 µM	—	Water	21
Colorimetry	5 ng mL ⁻¹	0.02–0.28 µg mL ⁻¹	—	Water	20
Colorimetry	30 ng mL ⁻¹	0.09–3.12 µg mL ⁻¹	15	Serum	19
Spectrofluorimetry	5 nM	60–240 nM	4	Urine, serum, injection form	This study

Carbon dots (CDs), a novel class of quantum dots (QDs), are fluorescent, zero-dimensional carbon nanoparticles less than 10 nm in size. They show significant potential in various fields due to their excellent properties, such as low or non-toxicity,²⁸ optical and chemical stability,²⁹ biocompatibility, environmental friendliness,³⁰ and high water solubility.^{31,32} CDs are especially valuable in sensing research, as their engineered surface functional groups provide specific molecular recognition capabilities. However, most reported CDs emit blue fluorescence, and their fluorescence is often quenched in the solid state due to aggregation. Red-emission carbon dots (R-CDs) offer advantages for various applications, but pure R-CDs with red emission in both solid state and aqueous solution have rarely been reported. Addressing these

challenges, this study synthesizes R-CDs and applies them as nanoprobe for detecting and quantifying HEP in human bio-fluids such as serum and urine, as well as in injection samples.


2. Experimental

2.1. Materials and apparatus

Details of the materials and apparatus are provided in the ESI.†

2.2. Synthesis of R-CDs

R-CDs were synthesized using a hydrothermal method. Briefly, a solution containing 0.1 g of thiourea and 0.1 g of

**Fig. 1** (a and b) TEM, (c) histogram (d) EDX and elemental mapping of the synthesized R-CDs.

neutral red (NR) dissolved in 20 mL of ultrapure water was prepared in a 50 mL Teflon-lined autoclave. The reaction mixture was heated at 180 °C for 3 hours. After the reaction, the crude product was centrifuged at 10 000 rpm for 20 minutes to remove impurities. The resulting clear supernatant was purified using dialysis bags (1000 Da) with ultrapure water for 48 hours. Finally, the R-CD solution was stored at 4 °C for further use.³³

2.3. HEP detection procedure

Fluorescence analysis was conducted as follows: 800 μ L of R-CDs was dissolved in phosphate buffer (PB) solution (10 mM, pH 6.0). Different aliquots (12–48 μ L) of HEP stock solution (1000 nM) were added to the prepared solution, and the final volume was adjusted to 2 mL with Milli-Q grade DI water. Four minutes after the final addition of HEP, the solution was transferred to a cell, and the fluorescence spectrum was recorded under excitation at 530 nm.

2.4. The measurement of interference

To evaluate the selectivity of the developed sensor for HEP, various substrates, including adenosine triphosphate (ATP), NaCl, Na₂HPO₄, Na₂CO₃, NaAc, glucose and sucrose, ascorbic acid, dopamine and cysteine (each at a concentration of 1200 nM), were mixed with 800 μ L of R-CDs and 200 μ L of phosphate buffer (PB) solution (pH 6.0, 10 mM). The final volume was adjusted to 2 mL with DI water. Under optimal conditions, the fluorescence spectrum was recorded with excitation at 530 nm.

2.5. Preparation of real samples

Urine and serum samples were collected from healthy, fasting 30 year-old female participants in accordance with ethical guidelines. The samples were separately centrifuged at 4000 rpm for 15 minutes. Then, 100 μ L of each centrifuged sample was diluted with deionized (DI) water in 10 mL volumetric flasks. HEP was added to these diluted samples to achieve final concentrations of 60, 160, and 240 nM. Additionally,




Fig. 2 (a) FT-IR spectra of NR and R-CDs, (b) UV-vis and (c) emission spectra of synthesized R-CDs.

a HEP sodium injection was diluted with deionized (DI) water to a final concentration of 1000 nM. All prepared samples were tested using the developed sensor, with each measurement performed in triplicate.

3. Results and discussion

3.1. Characteristics of the R-CDs

Various analyses were conducted to characterize the structural and morphological features of the synthesized nanoprobe. TEM images of R-CDs at different magnifications (Fig. 1a and b) show that the R-CDs are uniformly dispersed in spherical shapes without significant aggregation. This uniform distribution confirms the successful synthesis of the nanostructures. The average nanoparticle size was estimated to be 2.7 ± 0.06 nm, as depicted in the histogram of the R-CDs (Fig. 1c). EDX mapping (Fig. 1d) revealed the presence of carbon (C), oxygen (O), nitrogen (N), and sulfur (S) in the synthesized nanoprobe.

To further investigate the functional groups in the synthesized product compared to the primary substances, FTIR spectra of natural red (NR) and the synthesized R-CDs were recorded and are shown in Fig. 2a. Peaks around 3496 cm^{-1} , 1720 cm^{-1} , and 1210 cm^{-1} correspond to the stretching vibrations of O–H, C=O, and C–O–C, respectively.³⁴ The peak at 3296 cm^{-1} represents the stretching vibrations of N–H.

Additionally, peaks at 1551 cm^{-1} and 1412 cm^{-1} indicate the presence of C=C and C–N bonds.³⁵ Absorption peaks around 618 cm^{-1} , 1106 cm^{-1} , and 2918 cm^{-1} correspond to the stretching vibrations of C–S, C–O, and C–H, respectively.^{33,36}

The optical properties of the R-CDs were examined using UV-vis absorption (Fig. 2b) and emission spectra (Fig. 3b). As shown in Fig. 2b, the UV-vis absorption spectrum of the R-CDs displays a broad absorption band spanning from 400 to 600 nm, with a maximal absorption peak at 530 nm. This peak is attributed to the $n\text{--}\pi^*$ transitions of surface states containing C=O, C–O/C–N, and C–S structures.^{37,38} The R-CDs display optimal emission at 625 nm when excited at 530 nm (Fig. 3b). Therefore, 530 nm was chosen as the excitation wavelength for all experiments to ensure high sensitivity.

3.2. HEP detection using R-CDs

The primary objective of this study is to develop a novel strategy for HEP measurement using R-CDs as the nanoprobe. To evaluate the role of R-CDs in this approach, photoluminescence (PL) spectra for each substrate and their mixtures were recorded within the range of 500 nm to 800 nm. As shown in Fig. 3, a solution containing 100 nM of HEP does not exhibit emission spectra under 530 nm excitation, whereas a solution of R-CDs shows a peak at 625 nm under the same excitation. A mixture of R-CDs and phosphate buffer (PB, 20 mM, pH 6.0) exhibits a peak at 620 nm. The addition of 180 nM of HEP to this mixture results in a decrease in the intensity of the emission spectra, likely due to the interaction between buffer ions and the surface states of R-CDs, indicating the aggregation of R-CDs upon the introduction of HEP. A schematic illustration suggesting the selective detection mechanism of HEP by R-CDs is shown in Scheme 1.

3.3. Optimization of HEP detection using R-CDs

To achieve a stable maximum response, various analytical parameters, including excitation wavelength, pH, buffer type, nanoprobe volume, and incubation time for HEP detection, were optimized. Fig. 4a illustrates the fluorescence emission of the R-CD solution under different excitation wavelengths (λ_{ex}). Increasing λ_{ex} from 440 to 530 nm enhances the fluorescence emission intensity (λ_{em} around 625 nm); thus 530 nm was selected for maximum sensitivity. According to a recent study,³⁰ pH significantly influences the fluorescence intensity of R-CDs (Fig. 4b). Fluorescence intensity increases from pH 2.0, peaks at pH 6.0, and then decreases up to pH 9. Therefore,





Fig. 3 PL spectra of the different solutions: R-CDs, HEP (100 nM), a mixture of R-CDs and PB (20 mM) with pH of 6.0 in the absence and the presence of HEP.



Scheme 1 A schematic presentation for the selective detection of HEP by R-CDs.



measurements for HEP were performed at pH 6.0. Different 20 mM buffers (phosphate (PB), citrate (CB), and acetate (AB) buffers), at pH 6.0 were tested in a mixture of R-CDs (800 μ L) and HEP (12 μ L, 60 nM). The fluorescence emission spectra

indicated that PB provided the best medium for HEP detection (Fig. 4c). The effect of R-CD volume on sensor response in 20 mM PB (pH 6.0) containing HEP (60 nM) was examined, showing a decrease in intensity with the volume increasing




Fig. 4 (a) The fluorescence emission spectra of R-CD aqueous solution under different excitation wavelengths ranging from 440 to 550 nm. (b) Effect of different pH from 4.0 to 6.0. (c) Effect of different buffers including 20 mM of CB, PB and CA at pH of 6.0. (d) Effect of R-CD volume from 200 μ L to 1000 μ L in 20 mM PB (pH: 6.0) containing HEP (60 nM). (e) Effect of incubation time from 0 min to 6 min for 20 mM PB (pH: 6.0) containing HEP (140 nM) and 800 μ L of R-CDs.






Fig. 5 (a) The recorded absorbance spectra and (b) linear calibration curve for different concentrations of HEP ranging from 60 nM to 240 nM in the presence of the nanoprobe under the optimum conditions. (c) The response of the developed sensor towards HEP compared to ATP, NaCl, Na_2HPO_4 , Na_2CO_3 , NaAc, glucose, sucrose, ascorbic acid, dopamine and cysteine with 10-fold greater concentration than HEP (100 nM).

from 200 μL to 800 μL , followed by an increase from 800 μL to 1000 μL . Since 800 μL of R-CDs provided a stable minimum signal and demonstrated good interaction with HEP, this volume was chosen for further experiments (Fig. 4d). The effect of reaction time on 20 mM PB (pH 6.0) containing HEP (140 nM) and 800 μL of R-CDs showed that the intensity decreased upon HEP addition up to 2 minutes, after which it remained unchanged. Thus, 4 minutes was deemed sufficient for HEP detection (Fig. 4e).

3.4. HEP detection

One notable advantage of this study lies in its utilization of simple, cost-effective, and environmentally friendly materials for HEP assays. The detection process involved the straightforward addition of R-CDs as the nanoprobe under mildly acidic conditions. To assess the impact of increasing HEP concentration, varying concentrations of HEP were introduced to 800 μL of the buffered nanoprobe under optimized conditions. Fluorescence spectra were then recorded from 500 to 800 nm (Fig. 5a). As depicted in Fig. 5b, in the absence of HEP, the fluorescence intensity of the R-CDs remains robust in aqueous solution. However, the fluorescence intensity at 620 nm gradually diminishes with HEP concentration increasing from 60 nM to 240 nM, fitting the regression equation I (intensity in the presence of analyte)/ I_0 (intensity in the absence of analyte) = $-0.0017 [\text{HEP}] + 1.1084$, with a high correlation coefficient (R^2) of 0.9927. The limit of detection (LOD) was determined to be 5 nM based on $S/N = 3$. These calculated linear dynamic range (LDR) and LOD values are comparable to or exceed those reported for several sensors used in HEP detection across various real samples. The intense fluorescence of R-CDs in aqueous solution could be attributed to surface groups, such as hydroxyl, carboxyl, sulfur, or nitrogen. These groups likely interact with the negative sulfate and carboxylate groups present in HEP *via* electrostatic interactions, resulting in R-CD aggregation and fluorescence quenching.^{18,33}

3.5. Interference study

To evaluate selectivity, potential interfering substrates, including adenosine triphosphate (ATP), ATP, NaCl, Na_2HPO_4 , Na_2CO_3 , NaAc, glucose, sucrose, ascorbic acid, dopamine and cysteine, were prepared and tested using the proposed sensor. The results presented in Fig. 5c indicate that no species, at higher concentrations than HEP (60 nM), show any significant interference. Thus, the sensor is acceptably selective for HEP.

3.6. Detection of HEP in actual samples

To assess the practicality of the sensor in authentic samples, urine, human serum, and tablet specimens were prepared as outlined. Subsequently, 200 μL of each prepared sample was introduced to the R-CDs under optimized conditions, and the corresponding fluorescence spectra were captured using the standard addition technique. As detailed in Table 2, the determined concentrations of HEP in all samples closely matched the actual concentrations. The calculated recovery rates ranged from 95.41% to 106.71%, with RSD values below 3.00%, confirming the satisfactory feasibility of the developed sensor for HEP detection in real-world samples.

Table 2 Detection of HEP in human urine, serum samples and injection sample using the proposed sensor

Real sample	Spiked (nM)	Found (nM)	Recovery (%)
Urine	0.00	0.00	0.00
	100.0	99.78	99.78
	160.0	152.0	95.41
	240.0	244.0	102.0
Serum	0.00	0.00	0.00
	100.0	99.47	99.47
	160.0	159.0	99.39
	240.0	240.9	100.4
HEP injection form	0.00	6.10	—
	100.0	106.7	106.7
	160.0	166.4	104.0
	240.0	232.9	97.00



4. Conclusion

In summary, R-CDs were created as nanoscale probes, and their physical and chemical characteristics were examined using various methods. Multiple factors influencing the detection were optimized. These economical probes, which perform well in slightly acidic environments, were employed for the swift and easy identification of HEP over a wide concentration range. The straightforward and immediate monitoring of HEP in real human and drug samples showcases the promising analytical capabilities of the developed sensor.

Data availability

Data will be made available if requested. We are ready to make data available at any time.

Conflicts of interest

The authors declare no competing interests.

Acknowledgements

The authors appreciate the financial support from Tehran University of Medical Sciences, Tehran, Iran, to conduct this study.

References

- 1 J. Hirsh and R. Raschke, *Chest*, 2004, **126**, 188–203.
- 2 S. Faham, R. E. Hileman, J. R. Fromm, R. J. Linhardt and D. C. Rees, *Science*, 1996, **271**, 1116–1120.
- 3 R. E. Hurst, M. C. Poon and M. J. Griffith, *J. Clin. Invest.*, 1983, **72**, 1042–1045.
- 4 R. D. Rosenberg and P. S. Damus, *J. Biol. Chem.*, 1973, **248**, 6490–6505.
- 5 T. E. Warkentin, M. N. Levine, J. Hirsh, P. Horsewood, R. S. Roberts, M. Gent and J. G. Kelton, *N. Engl. J. Med.*, 1995, **332**, 1330–1335.
- 6 A. G. Turpie, J. G. Robinson, D. J. Doyle, A. S. Mulji, G. J. Mishkel, B. J. Sealey, J. A. Cairns, L. Skingley, J. Hirsh and M. Gent, *N. Engl. J. Med.*, 1989, **320**, 352–357.
- 7 D. J. Guervil, A. F. Rosenberg, A. G. Winterstein, N. S. Harris, T. E. Johns and M. S. Zumberg, *Ann. Pharmacother.*, 2011, **45**, 861–868.
- 8 A. Liveris, R. A. Bello, P. Friedmann, M. A. Duffy, D. Manwani, J. S. Killinger, D. Rodriguez and S. Weinstein, *Pediatr. Crit. Care Med.*, 2014, **15**, e72–e79.
- 9 S. Amemiya, Y. Kim, R. Ishimatsu and B. Kabagambe, *Anal. Bioanal. Chem.*, 2011, **399**, 571–579.
- 10 L. Fan, D. Jia, W. Zhang and Y. Ding, *Analyst*, 2020, **145**, 7809–7824.
- 11 D. W. Hommes, A. Bura, L. Mazzolai, H. R. Büller and J. W. ten Cate, *Ann. Intern. Med.*, 1992, **116**, 279–284.
- 12 S.-Y. Hung and W.-L. Tseng, *Biosens. Bioelectron.*, 2014, **57**, 186–191.
- 13 Q. G. Liao, W. H. Li and L. G. Luo, *Chromatographia*, 2013, **76**, 1677–1682.
- 14 L. Cai, R. Zhan, K.-Y. Pu, X. Qi, H. Zhang, W. Huang and B. Liu, *Anal. Chem.*, 2011, **83**, 7849–7855.
- 15 D. Liu, X. Guo, H. Wu and X. Chen, *Spectrochim. Acta, Part A*, 2024, **304**, 123255.
- 16 C.-Y. Kuo and W.-L. Tseng, *Chem. Commun.*, 2013, **49**, 4607–4609.
- 17 A. A. Abdella, A. M. Zaki, S. Hammad and F. R. Mansour, *Spectrochim. Acta, Part A*, 2024, **306**, 123609.
- 18 R. Wang, X. Wang and Y. Sun, *Spectrochim. Acta, Part A*, 2017, **184**, 187–193.
- 19 R. Cao and B. Li, *Chem. Commun.*, 2011, **47**, 2865–2867.
- 20 X. Fu, L. Chen, J. Li, M. Lin, H. You and W. Wang, *Biosens. Bioelectron.*, 2012, **34**, 227–231.
- 21 R. Zhan, Z. Fang and B. Liu, *Anal. Chem.*, 2010, **82**, 1326–1333.
- 22 R. Tabaraki and N. Sadeghinejad, *Ecotoxicol. Environ. Saf.*, 2018, **153**, 101–106.
- 23 L.-C. Feng, X.-X. Li, R. Chen, L.-L. Man and W.-K. Dong, *J. Mol. Struct.*, 2023, **1289**, 135941.
- 24 Y. Zhang, L. Tong, X. Li, L. Dou, H. Cheng, W.-K. Dong and Y.-J. Ding, *J. Mol. Struct.*, 2023, **1289**, 135868.
- 25 Y. X. Sun, W.-Y. Han, Z.-P. Deng, Y.-G. Sun, Y.-H. Jia, Y. Sun and S.-Z. Zhang, *Inorg. Chim. Acta*, 2023, **556**, 121643.
- 26 Y.-X. Sun, Y.-G. Sun, Z.-P. Deng, Y.-H. Jia, W.-Y. Han, J.-J. Wang and Y. Sun, *J. Mol. Struct.*, 2023, **1291**, 136069.
- 27 M. Mabrouk, S. F. Hammad, A. A. Abdella and F. R. Mansour, *Colloids Surf., A*, 2021, **614**, 126182.
- 28 M. J. Molaei, *Anal. Methods*, 2020, **12**, 1266–1287.
- 29 R. Kumari and S. K. Sahu, *Langmuir*, 2020, **36**, 5287–5295.
- 30 S. Wu, W. Li, Y. Sun, X. Pang, X. Zhang, J. Zhuang, H. Zhang, C. Hu, B. Lei and Y. Liu, *J. Mater. Chem. C*, 2020, **8**, 8935–8941.
- 31 X. Yuan, W. Jiang, J. Wang, H. Liu and B. Sun, *ACS Appl. Mater. Interfaces*, 2020, **12**, 25150–25158.
- 32 L. Li, X. Wang, Z. Ma, L. Liu, H. Wang, W. Zhang and X. Li, *Appl. Surf. Sci.*, 2019, **475**, 109–116.
- 33 L. Li, L. Shi, J. Jia, O. Eltayeb, W. Lu, Y. Tang, C. Dong and S. Shuang, *Sens. Actuators, B*, 2021, **332**, 129513.
- 34 P. Arabkhani, N. Saeedi, H. Sadeghi, S. Nouripour-Sisakht, M. Gharaghani and A. Asfaram, *J. Water Process Eng.*, 2023, **54**, 104020.
- 35 E. Kasiri, P. Arabkhani, H. Haddadi, A. Asfaram and R. S. Varma, *New J. Chem.*, 2022, **46**, 21704–21716.
- 36 W. Gao, H. Song, X. Wang, X. Liu, X. Pang, Y. Zhou, B. Gao and X. Peng, *ACS Appl. Mater. Interfaces*, 2018, **10**, 1147–1154.
- 37 G. Zuo, A. Xie, J. Li, T. Su, X. Pan and W. Dong, *J. Phys. Chem. C*, 2017, **121**, 26558–26565.
- 38 H. Yang, Y. Liu, Z. Guo, B. Lei, J. Zhuang, X. Zhang, Z. Liu and C. Hu, *Nat. Commun.*, 2019, **10**, 1789.

